AMSBIO announces a new range of ready-to-use Human induced Pluripotent Stem Cell (hiPSC) -derived cardiomyocytes, hepatocytes, and neurons. Supplied fully differentiated and available in high-purity formats, these ready-to-use cells help accelerate research by streamlining lab workflows, eliminating the need for in-house differentiation and minimizing preparation time.
Provided as functionally validated cells, researchers do not need to spend time on in-house validation and can instead apply them directly to their assays without additional steps. This is a major advantage for Contract Research Organizations (CROs) and life science labs who can save time and money on optimization work.
Outstanding batch-to-batch consistency ensures that AMSBIO’s iPSC-derived cells deliver reliable experimental outcomes every time. These hiPSC-derived cells provide a reliable and physiologically relevant alternative to primary cells and animal models, offering researchers a consistent and scalable source of cells for drug discovery, disease modelling, and toxicity screening.
For further information please visit https://www.amsbio.com/stem-cells/ipsc-derived-cells/ or contact AMSBIO on +31-72-8080244 / +44-1235-828200 / +1-617-945-5033 / info@amsbio.com.
